---
title: "Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286323165.md"
description: "TD Cowen analyst Tyler Van Buren has maintained a Buy rating on ORKA stock, citing strong clinical data for ORKA-001 in psoriasis, which showed a 64% PASI 100 response. Oruka's robust financial position, with $1.2 billion in cash, supports the development of ORKA-001 without immediate financing needs. Upcoming Phase IIa data and the Phase IIb EVERLAST-B readout in 2027 are expected to further validate its potential, which is estimated to be multi-billion-dollar. H.C. Wainwright also reiterated a Buy rating with a $120 price target."
datetime: "2026-05-13T21:55:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286323165.md)
  - [en](https://longbridge.com/en/news/286323165.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286323165.md)
---

# Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating on May 8.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tyler Van Buren has given his Buy rating due to a combination of factors tied to ORKA-001’s strong clinical profile and Oruka’s robust financial position. He highlights that ORKA-001 delivered a 64% PASI 100 response in the Phase IIa psoriasis study, meaning a large majority of patients achieved completely clear skin, exceeding benchmarks seen with Skyrizi and other leading therapies while maintaining a favorable safety and dosing profile.

He also notes that Oruka holds approximately $1.2 billion in cash, which he believes is sufficient to advance ORKA-001 through a biologics license application, supporting the view that the asset can be developed without near-term financing overhang. Additionally, he points to upcoming longer-term Phase IIa data in the second half of the year and the planned Phase IIb EVERLAST-B readout in 2027 as catalysts that could further validate annual dosing and a best-in-class profile, underpinning his view that ORKA-001 has multi‑billion‑dollar commercial potential.

In another report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $120.00 price target.

### Related Stocks

- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)

## Related News & Research

- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
- [Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock](https://longbridge.com/en/news/286877509.md)
- [DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments](https://longbridge.com/en/news/286923716.md)
- [02:41 ETSciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes](https://longbridge.com/en/news/286725647.md)
- [Stifel Nicolaus Sticks to Their Buy Rating for Target Hospitality (TH)](https://longbridge.com/en/news/286494923.md)